A Reversed-Phase High-Performance Liquid Chromatography Assay Procedure for Progabide and Its Related Metabolic Derivatives
- 1 January 1987
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 04 (1) , 28-32
- https://doi.org/10.1023/a:1016421725650
Abstract
A reversed-phase high-performance liquid chromatography (HPLC) assay procedure for Progabide, its active acid metabolite (PGA), and its hydrolytic degradation product (SL79.182) has been developed. This highly specific technique has allowed the simultaneous determination of these drugs in aqueous samples, and when coupled with a single and easy extraction step, spiked plasma samples could also be analyzed. The method had a sensitivity of about 30, 45, and 100 ng/ml for Progabide, SL79.182, and PGA, respectively.This publication has 7 references indexed in Scilit:
- The Stability and Solubility of Progabide and Its Related Metabolic DerivativesPharmaceutical Research, 1988
- Determination of progabide and its acid metabolite in biological fluids by high-performance liquid chromatography on silica column with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Measurement of progabide and its deaminated metabolite in plasma by high-performance liquid chromatogaphy and electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Gas chromatographic method for the determination of progabide (SL 76.002) in biological fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1982
- Pharmacokinetic Profile of Progabide, a New γ-Aminobutyric Acid-Mimetic Drug, in Rhesus MonkeyJournal of Pharmaceutical Sciences, 1982
- New anticonvulsants: Schiff bases of .gamma.-aminobutyric acid and .gamma.-aminobutyramideJournal of Medicinal Chemistry, 1980